



Aspira Pathlab & Diagnostics Limited

Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road,
Opp. Railway Station, Ghatkopar (W), Mumbai 400 086
CIN : L85100MH1973PLC289209

June 11, 2020

Corporate Relationship Department,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400 001.

Through: BSE Listing Centre

Scrip Code: 540 788

Sub: Disclosure of Material impact of COVID - 19 Pandemic on the Company under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Advisory vide Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated May 20, 2020

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulations, 2015 read with SEBI Advisory vide Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated May 20, 2020, we hereby submit an update by the Company giving brief details of the Material Impact of COVID-19 pandemic and the resultant lockdown, on the operations of the Company as an Annexure I.

We request you to disseminate the above information on your website.

Due to the prevailing situation amid COVID-19, this intimation is being filed under sd/-

Thanking you,

Yours faithfully,

For Aspira Pathlab & Diagnostics Limited

Sd/-

Mamta Mav

Company Secretary

Membership No. ACS 52501

Encl: As above.



Aspira Pathlab & Diagnostics Limited

Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road,
Opp. Railway Station, Ghatkopar (W), Mumbai 400 086
CIN : L85100MH1973PLC289209

ANNEXURE I

COVID-19 Pandemic and related developments - Update

With respect to the captioned subject, we hereby disclose the material impact of COVID-19 pandemic on the Company under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which is as follows:

1) Impact of COVID- 19 pandemic on Business:

Till March 15, 2020, the business operations were running more or less on a normal scale.

However, with the various restrictions imposed thereafter and also the lockdown announced from March 24, 2020, all the operations came to standstill during the rest of March. 2020.

In view of the lockdown during the latter part of the month, the sales achieved for the month of March 2020 and for first quarter of Financial year 2020-21.

This had its impact on the performance of the Company for Q4 .

2) Ability to maintain Operation

We were operating at sub optimal levels following Government directives on lockdown in March 2020. While most of the economic activity were at halt during the lockdown period, the healthcare sector continued operations under the Essentials Commodities Act. Accordingly, we continued to service our customers across channels.

As permissions on resumption and relaxations in the lockdown guidance came from May 2020 onwards, we witnessed an uptick in demand from our customers.

3) Schedule, if any, for restarting the operations:

As we are into Healthcare industry i.e. essential services, we have continued our operation in April and May 2020.

4) Steps taken to ensure smooth functioning of operations:

We have undertaken safety measures across our labs and collection centre and are following protocols to ensure our people are safe and secure. We have gradually been ramping up capacities across our laboratories, collection centre.



Aspira Pathlab & Diagnostics Limited

Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road,
Opp. Railway Station, Ghatkopar (W), Mumbai 400 086
CIN : L85100MH1973PLC289209

5) Estimation of the future impact of COVID-19 on its operations:

We believe there will be impact in revenue and profitability for Q1FY21 as our operations were partially operating in April 2020 and were gradually ramping up in May 2020.

Considering that the situation is exceptional and is changing dynamically, the Company is not in a position to gauge with certainty, the future impact on its operations. However, the Company is confident about adapting to the changing business environment and respond suitably to fulfil the needs of its customers.

6) Details of impact of COVID-19 on the Company:

a) Capital and Financial resources :

The company is planning to borrow from its Directors or Body Corporate for its working capital requirement.

b) Profitability :

The Profitability for the quarter 1 of Financial year 2020-21 is expected to be affected due to lockdown. However it is expected to improve from quarter 2 onwards.

c) Liquidity position:

There may be some impact on receivable cycle from B2B business, however, the company foresees no major risk on receivables. Our B2C business doesn't carry risk of recovery of assets since large part of the business is on cash and carry model.

d) Ability to service debt and other financing arrangements:

The Company endeavors for servicing the interest commitments.

e) Assets:

None of the assets of the Company have been impacted or impaired.

f) Internal financial reporting and Control:

The internal financial control over financial reporting and disclosure controls are maintained, continued and followed and there is no change in the same.

g) Supply Chain:

We have not observed any major supply chain issues and it is expected to normalize post lockdown.

h) Demand for Products/services:

There is temporary reduction in demand. However the same is expected to improve after the lock down gets over.



Aspira Pathlab & Diagnostics Limited

Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road,
Opp. Railway Station, Ghatkopar (W), Mumbai 400 086
CIN : L85100MH1973PLC289209

7) Existing contracts/agreements where non-fulfilment of the obligations by any party will have significant impact on the listed entity's business:

The Company is well positioned to fulfil its obligations and existing contracts/arrangements.

This update is dynamic and may change as the situation changes. The company will provide an update on the situation in case of any major change.